<DOC>
	<DOCNO>NCT02029690</DOCNO>
	<brief_summary>A study ADI-PEG 20 ( pegylated arginine deiminase ) , arginine degrade enzyme patient histologically proven advanced malignant pleural mesothelioma ( MPM ) , advanced peritoneal mesothelioma ( dose escalation cohort ) , non-squamous non-small cell lung carcinoma stage IIIB/IV ( NSCLC ) , metastatic uveal melanoma , hepatocellular carcinoma ( HCC ) , glioma sarcomatoid cancer</brief_summary>
	<brief_title>Ph 1 Study Subjects With Tumors Requiring Arginine Assess ADI-PEG 20 With Pemetrexed Cisplatin</brief_title>
	<detailed_description>Weekly ADI-PEG 20 cohort dose escalate ( 18 , 27 36 mg/m2 ) , pemetrexed 500 mg/m2 cisplatin 75 mg/m2 give every 3 week . Subjects may receive maximum 6 , 3-week cycle ADIPemCis total 18 week treatment . Subjects NSCLC may receive 4 6 , 3-week cycle per local institutional policy . Those subject complete ADIPemCis treatment may continue ADI-PEG 20 monotherapy SD well . Subjects NSCLC may continue receive pemetrexed per local institutional policy along ADI-PEG 20 and/or continue ADI-PEG 20 monotherapy pemetrexed also discontinue .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Histologically proven advance MPM , advance peritoneal mesothelioma ( dose escalation cohort ) nonsquamous NSCLC ( stage IIIB/IV ) treat prior chemotherapy immunotherapy , except NSCLC subject EGFR mutant ALK positive must EGFR tyrosine kinase inhibitor ( TKI ) ALK inhibitor progress show intolerant therapy prior enrol trial , ALK inhibitor EGFR target therapy approve available country patient enrol OR Histologically proven metastatic uveal melanoma treat prior chemotherapy ( MTD cohort ) , OR Histologically proven HCC fail ( PD and/or side effectsbeen intolerant ) treatment sorafenib . Failure define progress radiographically , intolerant prior systemic therapy . Intolerance defined discontinuation due AE ( ) prior systemic therapy unacceptable treat physician / patient , without dose interruption modification . Failure require least 14 day treatment sorafenib , except subject severe allergic reaction sorafenib time , even less 14 day treatment sorafenib thus would imprudent rechallenge agent . Cirrhotic status ChildPugh grade AB7 must present . ChildPugh status determine base clinical finding laboratory data screen period ( Appendix E ) . Subjects anticoagulant receive 1 point INR status , presume &lt; 1.7 baseline PT/INR . `` , OR Histologically proven highgrade glioma fail ( PD and/or side effect ) treatment radiotherapy ± temozolomide , OR Sarcomatoid cancer line . 2 . ASS1 deficiency ( define ≤50 % ASS expression ) demonstrate tissue specimen ( cytospin sample acceptable ) immunohistochemistry ( IHC ) . For subject previously treat chemotherapy , specimen may obtain chemotherapy . A new tissue specimen obtain recent chemotherapy require . Thus ASS1 deficiency require entrance study . If tissue available determine ASS1 deficiency , tissue must obtain biopsy determine ASS1 status . 3 . Measurable disease assess modified RECIST MPM RECIST 1.1 criterion peritoneal mesothelioma , NSCLC , uveal melanoma , HCC , glioma sarcomatoid carcinoma 4 . ECOG performance status 0 1 5 . Predicted life expectancy least 12 week . 1 . Radiotherapy ( except palliative reason ) , target therapy , immunotherapy ( except uveal melanoma ) previous four week study treatment . 2 . Ongoing toxic manifestation previous treatment . 3 . Symptomatic brain spinal cord metastasis ( patient must stable &gt; 3 month post radiotherapy surgery ) subject mesothelioma , NSCLC , uveal melanoma exclude subject HCC glioma ) . 4 . Major thoracic abdominal surgery patient yet recover . 5 . Serious infection require treatment intravenous antibiotic time study entrance , infection require intravenous therapy within 7 day prior first dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>argininosuccinate synthetase</keyword>
	<keyword>arginine</keyword>
	<keyword>arginine deiminase</keyword>
</DOC>